Table 3 Results of the modified Delphi: 10 topics that the committee agreed to address
1Diseases to be addressedWG, MPA, CSS, PAN, cryoglobulinemic vasculitis, GCA, Takayasu arteritis
2Initial assessmentInvolvement of expert centres, structured clinical examination, role of ANCA, staging of disease, biopsy
3Remission inductionCyclophosphamide, methotrexate, high-dose glucocorticoids
Doses, route of administration, regimen of intravenous use, prophylaxis against Pneumocystis jiroveci and osteoporosis, tapering of glucocorticoids, bladder protection, antiemetic therapy, monitoring for drug toxicity, plasmapheresis
4Remission maintenanceChoice of immunomodulator, length of treatment, co-trimoxazole
5Relapsing diseaseChoice of immunomodulator, referral to expert centre
6Refractory diseaseChoice of immunomodulator, experimental therapies
7Cryoglobulinemic vasculitisChoice of therapy, antiviral therapy
8Polyarteritis nodosaChoice of therapy, antiviral therapy
9Monitoring and follow-upStructured clinical examination, blood test monitoring, urine analysis, vaccination, fertility and contraception
10Complications of diseaseAnaemia, hypertension, thromboprophylaxis, reconstructive surgery, renal protection
  • ANCA, anti-neutrophilic cytoplasmic antibodies; CSS, Churg–Strauss syndrome; GCA, giant cell arteritis; MPA, microscopic polyangiitis; PAN, polyarteritis nodosa; WG, Wegener granulomatosis.